Overview of Eczacort

Property	Description
Active ingredient	Hydrocortisone (INN)
Form	Cream, Ointment, or Lotion
Pharmacological class	Glucocorticosteroid / Corticosteroid
Common use	Relief of Inflammation and Pruritus
Origin	Semi-synthetic (derived from natural cortisol)

What Type of Medicine is Eczacort?

Eczacort is a topical medicinal preparation classified as a glucocorticosteroid or corticosteroid, used primarily as an anti-inflammatory agent. It is fundamentally a synthetic compound derived from the natural hormone cortisol, which the human body's adrenal glands produce. Eczacort is often marketed in lower strengths as an Over-the-Counter (OTC) product, distinguishing it from higher-potency prescription corticosteroids like Betamethasone. This pharmacological classification places Eczacort within a group of medicines clinically recognized for their effectiveness at suppressing inflammation and localized immune activity. This preparation is specifically intended for application to the skin surface for managing conditions associated with excessive inflammation.

Composition: What is the Active Ingredient in Eczacort?

The sole active ingredient in Eczacort is Hydrocortisone (INN), meaning it is manufactured as a single-ingredient product. The chemical structure of Hydrocortisone, C21H30O5, is well-established. Hydrocortisone is classified as a semi-synthetic derivative because it is produced industrially to mimic and modify the structure of the naturally occurring cortisol hormone. Eczacort is typically supplied in one of several dosage forms, most commonly a cream, ointment, or lotion, all designed for the topical route of administration. The specific base—such as a cream or ointment—serves as the vehicle that allows the Hydrocortisone to be delivered effectively to the skin.

General Therapeutic Purpose and Core Action

The general purpose of Eczacort is to provide rapid symptomatic relief by controlling the localized inflammation and pruritus (itching) caused by various dermatological conditions. As a corticosteroid, Eczacort works by modulating the body’s immune response directly within the skin cells, which effectively diminishes the production of inflammatory signals. Topical corticosteroids are an effective treatment for the reduction of swelling and itching associated with skin conditions. This means the medicine is reliably shown to ease discomfort by controlling the underlying inflammatory reaction. This action helps to reduce the visible symptoms of skin irritation, such as intense redness and swelling, making it a key therapeutic option for managing reactive skin states, such as localized skin irritation following exposure to allergens.

What side effects are possible with Eczacort?

Possible Side Effects and Safety Information

The safety profile for Eczacort (topical hydrocortisone) primarily involves reactions at the application site and the potential for systemic effects from absorption, as documented in official regulatory labeling. These adverse reactions are classified across various organ systems.

Official Adverse Reactions and Classifications

Adverse reactions are broadly classified, often with an incidence Not Known, into two key System-Organ Classes:

Skin and subcutaneous tissue disorders: This class covers local effects such as burning, itching (pruritus), irritation, dryness, folliculitis, and acneiform eruptions. With prolonged use, structural skin changes like skin atrophy (thinning) and striae (stretch marks) are documented.
Endocrine disorders: This category addresses systemic absorption risks, including the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations resembling Cushing's syndrome. These are considered serious adverse reactions in the regulatory context.

Time-Related Patterns and Population Risk

Official safety statements explicitly link increased risk to the duration and extent of use. The risk of systemic effects and skin atrophy is augmented by prolonged use, application to large surface areas, or use under occlusive dressings. Pediatric patients are officially noted to be more susceptible to systemic toxicity, including potential interference with growth and development, due to their higher skin surface area to body weight ratio.

Regulatory labeling also includes restrictions, noting that the product should not be used on sites with untreated infections and must be kept away from the eyes due to documented risks of Cataracts and Glaucoma.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Eczacort is related to the potential for systemic absorption when the topical preparation is used in excessive quantities, over large surface areas, or for prolonged durations. This excessive absorption can disrupt the body's natural hormone balance, potentially leading to Cushing’s Syndrome or adrenal suppression (secondary adrenocortical insufficiency).

Signs and symptoms associated with systemic overdose or toxicity may include:

Endocrine effects: Unusual tiredness or weakness, increased thirst and urination, and dizziness.
Cardiovascular and CNS changes: Fast, irregular, or pounding heartbeat, and blurred vision.

Emergency Actions Required

Situation	Action to Take
Accidental ingestion or suspected systemic overdose	Immediately contact a certified Poison Control Center or emergency medical services.
Signs of life-threatening events	Call your local emergency number (e.g., 911) immediately if the person collapses, has a seizure, is having severe trouble breathing, or cannot be awakened.

Children may be more susceptible to systemic toxicity, including the risk of adrenal suppression and Cushing’s Syndrome, due to their higher skin surface area to body weight ratio. In any case of suspected overdose or the manifestation of the listed serious symptoms, urgent medical attention is required. Do not wait for symptoms to worsen before seeking professional help.

Therapeutic Uses of Eczacort

What Eczacort Treats: Main Uses and Benefits

Eczacort (topical hydrocortisone) is applied across therapeutic domains involving localized skin reactions, providing symptomatic support to ease the overall symptom burden. Hydrocortisone topical is used to address symptoms of various skin conditions.

The preparation is commonly used to help with conditions characterized by an underlying inflammatory process, such as atopic dermatitis (eczema), contact dermatitis, seborrheic dermatitis, and limited, mild psoriasis. It is applied in clinical settings where additional symptomatic support is needed to address pronounced manifestations of redness and swelling that are part of acute or recurrent episodes.

Eczacort is considered relevant in clinical settings marked by certain distressing symptoms of intense itching (pruritus), which is a common symptom that can interfere with daily functioning. It helps address symptom clusters that lead to temporary functional strain, and offers symptomatic relief that may assist with maintaining functional stability during episodes of heightened symptoms.

Quick Fact: Relief for Pruritus

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Population Eligibility Rules

Eczacort (topical hydrocortisone) use is defined by official regulatory documents based on patient population, age, and existing conditions. It is contraindicated for patients with a documented hypersensitivity to any component of the preparation. Use is also absolutely prohibited on skin areas with untreated infections, including bacterial, fungal, or viral conditions such as herpes simplex or chickenpox, as well as on skin affected by rosacea, acne vulgaris, or perioral dermatitis. The medicine is not intended for use against pruritus (itching) that lacks underlying inflammation.

Age Group	Eligibility Status (Regulatory Wording)
Children under 2 years	Not recommended; use requires consultation with a doctor due to a greater risk of systemic absorption and potential effects on growth.
Adults and Older Children	Use is allowed, but caution is required, particularly with prolonged use or application over large areas, which may lead to systemic effects.

Pregnancy and Lactation: Use during pregnancy should occur only if the potential benefit justifies the potential risk to the fetus. Caution must be exercised when the medicine is administered to a nursing woman, and application to the breast area must be avoided prior to feeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Eczacort (topical hydrocortisone) focuses on risks stemming from systemic exposure, which is generally low but is subject to documented modification. Interactions are categorized based on their mechanism and the potential for increased risk, rather than formal contraindications.

Pharmacodynamic Interactions

Co-administration with other systemic or high-potency topical glucocorticosteroids creates an additive pharmacodynamic risk. This combination increases the likelihood of systemic toxicity, such as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. Concurrent use with Potassium-depleting Agents (e.g., certain diuretics) may result in an augmented risk of hypokalemia if significant systemic absorption occurs.

Exposure-Modifying Substances and Conditions

Category	Officially Documented Interaction/Restriction
Pharmacokinetic Risk	Co-administration with Potent CYP3A4 Inhibitors (e.g., ketoconazole) may inhibit the metabolism of absorbed hydrocortisone, leading to a documented risk of increased systemic exposure (elevated blood levels).
Procedural Restriction	The use of Occlusive Dressings (e.g., bandages, tight-fitting diapers) is designated as significantly increasing percutaneous absorption, which elevates the risk of all systemic interactions.

Population-Specific Interaction Notes

Official labeling recognizes that Pediatric Patients and individuals with Hepatic Impairment (liver failure) are at an increased risk for systemic interactions, such as HPA axis suppression, due to physiological factors that heighten absorption or reduce metabolism.

Mechanism of Action

How Eczacort Works

Eczacort is a Nuclear Receptor NR3C1 ligand. Its mechanism of action begins with selective binding to the glucocorticoid receptor NR3C1, facilitating the translocation of the bound receptor complex into the cell nucleus. This interaction results in the inhibition of mathbfpro-inflammatory mathbftranscription mathbffactor mathbfactivity through two primary processes: transrepression and transactivation.

Via transrepression, Eczacort binding modulates the activity of key pro-inflammatory factors, such as NFkappa B, limiting their ability to activate target genes. Concurrently, it exerts an mathbfinhibitory mathbfeffect on the expression of downstream cytokines (IL-6, TNFalpha, IL-1beta), thereby mathbfmodulating mathbfcytokine mathbftranscription. This comprehensive molecular cascade reduces the synthesis of mathbfpro-inflammatory mathbfmediators at the cellular level, leading to systemic physiological modulation of cellular responses.

Dosage and Administration Information

The usage protocol for Eczacort (topical hydrocortisone) focuses on specific, controlled application parameters.

Administration Scope

Instruction	Detail
Route of administration	Topical (application to the affected skin area only).
Dosing schedule	Apply a thin film of the preparation to cover the affected area. Common strengths are 1% and 2.5%.
Frequency	Typically administered two to four times daily.
Preparation requirements	The choice between cream or ointment may be guided by the lesion type, with ointments often used for dry lesions.
Age-group administration rules	Use in pediatric patients should be restricted to the minimum effective amount. General use is not recommended for children under two years of age.
Missed-dose rules	If an application is missed, it is skipped if nearly time for the next dose; a double amount must not be applied.
Special procedural conditions	External use only. Contact with the eyes must be avoided. The treated area must not be covered with occlusive dressings unless specifically directed.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Topical
Frequency pattern	Multiple times daily (typically 2 to 4 times daily).
Use-context constraints	Short-term use (generally limited to seven days for continuous application). Requires reassessment if no improvement occurs within two weeks.

Connection to the overall use protocol

The instructions define Eczacort as a focused, time-bound therapy with a precise application schedule. The protocol involves applying a minimal quantity of the appropriate formulation directly to the affected area while avoiding covering the site to control absorption. This framework outlines a standardized administration period, requiring clinical re-evaluation if the usage does not achieve condition control within the specified timeframe.

Recent Clinical Evidence

Eczacort (topical hydrocortisone) has been studied in research primarily focused on conditions characterized by fluctuating or episodic inflammation.

Evidence for Core Indications

For Atopic Dermatitis (Eczema) Flares, research explored the compound in short-term Randomized Controlled Trials (RCTs) and systematic reviews, mainly involving adult and pediatric populations with mild to moderate disease severity. Studies monitored patient-reported outcomes describing discomfort and outcomes linked to inflammatory or irritative states, reporting measurements of changes over short periods, typically only a few weeks. The overall evidence includes trials that studied the compound alongside a vehicle (placebo) or alongside other topical agents.

Research explored the compound in localized Psoriasis, primarily in mild presentations. These trials studied the low-potency compound alongside other treatments, focusing on visible characteristics such as scaling and inflammation. However, existing evidence provides limited insight into the evaluation of low-potency hydrocortisone in treating moderate to severe or extensive psoriasis.

For Other Corticosteroid-Responsive Dermatoses, the evidence is often derived from pharmacological studies, which focused on whether the compound was associated with changes in localized inflammatory states. These studies often relied on laboratory tests as a proxy for anti-inflammatory activity rather than large, modern clinical trials for every individual subtype.

Research Gaps and Uncertainty

Across the evidence base, the majority of studies are relevant in trials assessing short-term symptom patterns, meaning the follow-up durations were limited. Long-term effects remain uncertain, and certainty remains low regarding sustained, continuous use beyond short, defined treatment courses. Research has explored the compound in studies involving pediatric patients with mild to moderate disease. However, data for certain groups, such as infants, older adults, or individuals with severe disease, remain insufficient, and results apply only to the specific populations studied.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Eczacort (FAQ)

Q: Does Eczacort come in different forms, like cream or pill?

Eczacort is classified as a topical preparation, meaning it is designed to be applied only to the skin surface. The official product forms are preparations like cream, ointment, or lotion. There is no oral (pill) form of Eczacort available for use.

Q: Is Eczacort only for long-term use?

No, official regulatory guidance indicates Eczacort is intended for short-term use. Regulatory protocol often defines a specific, short period of use for continuous application, such as up to a week. Long-term therapy or use beyond the specified period is generally advised against due to safety considerations.

Q: Is it normal to feel a mild burning sensation when first applying Eczacort?

A mild burning or irritation sensation where the medicine is applied is listed as a common adverse reaction in the official product labeling. This effect is often local to the application site and is sometimes felt when the medicine is first used.

Q: Can I use Eczacort on my face or sensitive areas?

Official guidelines generally advise caution or advise against using Eczacort on highly sensitive or large surface areas, such as the face, underarms, or groin. This restriction relates to the potential for increased absorption and side effects in these sensitive locations.

Q: What are the known potential long-term risks of Eczacort?

Risks documented in official sources are linked to prolonged or excessive use. These potential long-term risks include skin atrophy (thinning of the skin) and systemic effects like HPA axis suppression, which is an effect on the body's natural hormone regulation. Excessive absorption may also lead to manifestations resembling Cushing's syndrome.

Q: Do I need a prescription to get Eczacort?

Eczacort (hydrocortisone topical) is available in different strengths, which dictates its regulatory status. Depending on the strength and location of sale, it may be available over-the-counter (OTC) or require a prescription from a healthcare provider.

Q: Is Eczacort available over the counter in some places?

Yes, in many regions, the lower strengths of Eczacort (hydrocortisone topical) are commonly classified as available for purchase without a prescription (Over-the-Counter). Higher strengths usually require a prescription.

Q: Is Eczacort known to cause weight gain?

Weight gain is not listed as a common local side effect of Eczacort. However, it is a documented clinical feature associated with the serious and rare systemic adverse reaction known as Cushing's syndrome, which is a risk when the medicine is used for a long period.

Q: Can taking Eczacort make you feel tired or dizzy?

While tiredness or dizziness are not listed as common local reactions, they can be signs of more serious systemic adverse effects. These effects may occur if there is excessive absorption of the medicine into the body, which may be associated with excessive systemic absorption.

Q: Is there a maximum amount of time someone can safely use Eczacort?

Official labeling specifies a maximum continuous application period, often limiting use to around seven days. If the condition has not improved following the defined period, official labeling often indicates that re-evaluation by a healthcare professional is needed.

Q: What should I do if I use too much Eczacort by mistake?

Official guidance warns against using Eczacort for longer than directed or over a large area, as this increases the risk of systemic side effects. Official guidance emphasizes using the medicine only as directed because this helps avoid the potential for unwanted effects from increased systemic absorption.

Q: Does Eczacort contain gluten or lactose?

The official product labeling (such as the SmPC or DailyMed entry) includes the full list of inactive ingredients (excipients) used in the specific formulation. This document contains the necessary factual information to check for the presence of ingredients such as lactose or gluten.

Q: How quickly does Eczacort leave the body?

Pharmacological data describes the systemic half-life of the active ingredient (hydrocortisone) when it is absorbed into the body. This measure, the time it takes for half of the substance to be eliminated, is approximately 8 to 12 hours.

Q: Are there different strengths of Eczacort available?

Yes, official labeling shows Eczacort (hydrocortisone topical) is available in a range of concentrations or strengths. These commonly include 0.5%, 1%, and 2.5% for the various topical preparations.

Q: Is there a rebound effect when stopping Eczacort?

Stopping treatment, particularly when it has been used for prolonged and continuous periods, is associated with the potential for a rebound effect. This is a temporary return of symptoms, which is a key feature of Topical Steroid Withdrawal (TSW) as a clinical phenomenon.

Q: Does Eczacort have a risk of addiction or dependence?

Eczacort is not classified as an addictive substance or a controlled drug. However, the use of topical corticosteroids for prolonged periods can lead to physical changes, such as HPA axis suppression and Topical Steroid Withdrawal (TSW), which are sometimes mistaken for dependence.

Q: What are the requirements for storing Eczacort?

Official instructions state that Eczacort must be stored at Controlled Room Temperature (typically 20 C to 25 C). The product must be kept out of the sight and reach of children and protected from excess heat and freezing.

Q: Is Eczacort considered a high-potency medicine?

No, official regulatory classification systems generally define Eczacort (hydrocortisone topical) as a mild or least potent corticosteroid.

Q: What does the official patient leaflet say about driving while using Eczacort?

Because Eczacort is applied to the skin and systemic absorption is typically low, official patient information leaflets for topical hydrocortisone products generally do not contain a specific warning about effects on the ability to drive or operate machinery.

Q: Are there any limitations on the area of skin Eczacort can be applied to?

Official warnings relate to application over a large surface area or for prolonged periods. This guidance exists because these usage patterns may be associated with an increased risk of systemic side effects due to increased absorption.

Q: Is it safe to get vaccinated while using Eczacort?

Warnings about potential interference with vaccines are typically reserved for patients receiving high-dose systemic corticosteroids. Standard patient information generally does not list topical hydrocortisone as interfering with vaccination.

Q: Does Eczacort lose its effectiveness over time?

Continuous application of Eczacort over extended periods of time is associated with the clinical phenomenon of tachyphylaxis. Tachyphylaxis is documented as a rapid decrease in the medicine's response, which may result in the medicine appearing to lose its effectiveness.

Q: What are the official clinical trial results for Eczacort's primary use?

Official clinical trial data is contained within regulatory submissions and public trial registries. These documents detail the efficacy (how well the medicine works) and safety outcomes for the primary conditions Eczacort is used to manage, such as mild to moderate atopic dermatitis.

Q: Do people with diabetes need special monitoring while using Eczacort?

Official warnings state that patients with diabetes or high blood sugar must use Eczacort with caution. Official warnings indicate that systemic absorption may affect blood sugar control. For this reason, official information often references the need for close monitoring of blood sugar levels in these patients.

Q: Has Eczacort been reviewed by regulatory bodies like the FDA?

Yes, Eczacort (hydrocortisone topical) products are included in the guidelines and documentation of major regulatory bodies. This confirms the products have been subject to review and approval by agencies such as the U.S. Food and Drug Administration (FDA).

Q: Is Eczacort a treatment or a cure for the condition?

Eczacort is classified as a treatment used to manage the symptoms of inflammatory skin conditions, such as reducing inflammation and itching. It is not considered a cure for the underlying medical conditions it is used to address.

Q: What kind of research has been done on Eczacort?

The research base for Eczacort includes various types of controlled clinical studies. These typically involve Randomized Controlled Trials (RCTs) that focus on evaluating the compound's safety and effectiveness against its primary medical uses.

How should Eczacort be stored and disposed of?

Eczacort (topical hydrocortisone) must be stored and handled according to the instructions on its official regulatory label to maintain its stability.

Storage Conditions and Handling

Requirement	Official Instruction
Temperature	Store at Controlled Room Temperature (20 C to 25 C), or as stated on the label (e.g., below 25 C).
Protection	Keep the medicine out of direct light and away from excess heat and moisture.
Freezing	Do not freeze or keep the product from freezing.
Child Safety	Must be kept out of the sight and out of reach of children.
Container	Keep the medicine in its original container and tightly closed.

Disposal Instructions

When disposing of unused or expired Eczacort, follow local requirements for pharmaceutical waste. The U.S. FDA recommends using a drug take-back program as the preferred method.

If a take-back option is unavailable, the medicine should not be flushed down the toilet. Instead, it can be discarded in the household trash after being mixed with an undesirable substance (such as used coffee grounds or dirt) and sealed in a bag or container.

Eczacort